Publications

In 1978, while at the University of Texas, Dr. Lamm along with Dr. Pinsky of Memorial Sloan Kettering Cancer Center, was awarded the first NIH-funded contract to evaluate BCG immunotherapy of superficial bladder cancer in a randomized clinical trial. This work resulted in the first controlled trial demonstrating the efficacy of intravesical BCG immunotherapy.

Dr. Lamm continues his research in BCG immunotherapy and chemoprevention, including a clinical trial showing reduced tumor recurrance in BCG patients adminstered megadoses of vitamins

2005 Publications

• Donald L. Lamm, MD, FACS. BCG Immunotherapy of Superficial Bladder Cancer. Contemporary Urology. February, 2005.
  A comprehensive review of the history of BCG and its practical application in superficial bladder cancer.
• Murray S Feldstein, M.D. and Donald L Lamm M.D. Chapter 23: BCG maintenance for bladder tumours: what schedule and is it worthwhile? The Evidence for Urology. Dawson and Muir, editors, Gutenberg Press, Malta.
  This text of evidenced-based medicine in urology is used to guide treatment decisions. A systematic review of the literature on BCG therapy revealed overwhelming evidence that BCG reduces tumor recurrence
• Coming Soon! Thomas F. Hogan, M.D., Donald L. Lamm, M.D., and Daniel Rubin, N.D. Integrative Tumor Board: Transitional Cell Carcinoma of the Bladder. Complimentary Medicine.
  A multidisciplinary approach to a difficult management problem, utilizing medical oncology, urology, and nutrition/complimentary medicine approaches.
• Coming Soon! SIU/ICUD:2004 International Consensus Conference on Bladder Cancer: T1 Report. Alan M. Nieder , M.D., Maurizio Brausi, M.D., Donald Lamm, M.D., Michael O'Donnell, M.D., Kyouichi Tomita, M.D., Henry Woo, M.D., and Michael A.S. Jewett, M.D.
  The international consensus on the management of lamina-propria invasive bladder cancer meeting was held in October, 2004. The report, to be published this year, compares BCG to cystectomy.

  More Publications